MESTINON
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
MESTINON by Bausch + Lomb is actions: mestinon inhibits the destruction of acetylcholine by cholinesterase and thereby permits freer transmission of nerve impulses across the neuromuscular junction. First approved in 1955.
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MESTINON (pyridostigmine) is a cholinesterase inhibitor that enhances acetylcholine transmission across the neuromuscular junction, enabling freer nerve impulse transmission. Administered via injection, it is indicated for myasthenia gravis and related neuromuscular disorders. The drug has been a standard of care since FDA approval in 1955, offering longer duration of action and fewer gastrointestinal side effects compared to neostigmine.
LOE Approaching
As a long-established therapy approaching loss of exclusivity with moderate competitive pressure (30), brand teams should anticipate resource optimization and transition toward generic support or market exit strategies.
Mechanism of Action
ACTIONS: MESTINON inhibits the destruction of acetylcholine by cholinesterase and thereby permits freer transmission of nerve impulses across the neuromuscular junction. Pyridostigmine is an analog of neostigmine (Prostigmin), but differs from it in certain clinically significant respects; for…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Testing Mestinon and Exercise in Fibromyalgia
Started Sep 2002
178 enrolled
Fibromyalgia
Career Relevance
Working on MESTINON offers limited growth trajectory but provides stability in a niche therapeutic area with loyal prescriber base and established market dynamics. This role is best suited for professionals comfortable with mature product management, generic conversion strategy, and operational efficiency rather than commercial expansion.
Brand Manager
Worked on MESTINON at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.